Supernus’s stock sinks after depression drug fails trial
The Phase IIb trial missed its primary endpoint in patients with treatment-resistant depression.
mental health conditions
Concentric Analgesics highlights data on vocacapsaicin for pain relief
Study finds semaglutide decreases tobacco-related healthcare
FDA approves Luye Pharma’s ERZOFRI for schizophrenia
Johnson & Johnson submits sNDA for SPRAVATO to treat depression
Enveric Biosciences to out-license psilocin prodrug to MindBio
Clearmind licenses psychedelic compounds for mental disorders
Enveric’s EB-003 selected as lead candidate for mental health disorders
